间充质干细胞治疗脓毒症性急性肺损伤的基础研究和临床应用进展

Basis and clinical progress in mesenchymal stem cells for acute lung injury caused by sepsis

脓毒症性急性肺损伤是一种严重威胁患者生命的疾病,其发病率和病死率均较高,是临床治疗的重点和难点。传统治疗方法存在局限性,因此迫切需要寻找新的治疗途径。间充质干细胞疗法作为一种有潜力的细胞治疗方法引起了广泛的关注,研究表明间充质干细胞治疗在人类患者中具有潜在疗效,且安全性较高。然而,仍然存在一些挑战和有待解决的问题,如间充质干细胞的来源和制备、最佳的治疗方案以及治疗机制等。本文主要综述了间充质干细胞治疗脓毒症性急性肺损伤的机制,临床研究及其临床应用的挑战,旨在更好地了解间充质干细胞治疗脓毒症性急性肺损伤的前景和潜力,为临床实践提供新的思路和依据。

Sepsis acute lung injury is a life-threatening disease with high morbidity and mortality,which is a major difficulty in clinical treatment.There are limitations of traditional treatment methods,so it is urgent to find new therapeutic approaches.Mesenchymal stem cell therapy,as a potentially effective cellular treatment,has attracted much attention.Studies have shown that mesenchymal stem cell therapy has potential therapeutic effects on human patients and is relatively safe.However,there remain some challenges and questions,such as the origin and preparation of mesenchymal stem cells,the best treatment regimen,and the mechanism of treatment.This review summarized the mechanism of mesenchymal stem cell therapy for sepsis-induced acute lung injury,research,and challenges in clinical application,aiming to better understand the prospect of mesenchymal stem cell therapy for sepsis-induced acute lung injury,and provide new ideas for clinical practice.